BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ocean AJ, Christos P, Sparano JA, Shah MA, Yantiss RK, Cheng J, Lin J, Papetti M, Matulich D, Schnoll-Sussman F. Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Invest New Drugs. 2014;32:542-548. [PMID: 24526575 DOI: 10.1007/s10637-014-0070-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang XS, Kong DJ, Lin TY, Li XC, Izumiya Y, Ding XZ, Zhang L, Hu XC, Yang JQ, Gao SG, Lam KS, Li YP. A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer. Acta Pharmacol Sin 2017;38:931-42. [PMID: 28552907 DOI: 10.1038/aps.2017.43] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
2 Chen P, Luo X, Nie P, Wu B, Xu W, Shi X, Chang H, Li B, Yu X, Zou Z. CQ synergistically sensitizes human colorectal cancer cells to SN-38/CPT-11 through lysosomal and mitochondrial apoptotic pathway via p53-ROS cross-talk. Free Radical Biology and Medicine 2017;104:280-97. [DOI: 10.1016/j.freeradbiomed.2017.01.033] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 7.6] [Reference Citation Analysis]
3 Gulley ML. Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma. Exp Mol Med. 2015;47:e134. [PMID: 25613731 DOI: 10.1038/emm.2014.93] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
4 Lazăr DC, Tăban S, Cornianu M, Faur A, Goldiş A. New advances in targeted gastric cancer treatment. World J Gastroenterol 2016; 22(30): 6776-6799 [PMID: 27570417 DOI: 10.3748/wjg.v22.i30.6776] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
5 Aras B, Yerlikaya A. Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3. Oncol Lett 2016;11:3179-84. [PMID: 27123085 DOI: 10.3892/ol.2016.4340] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
6 Sexton RE, Hallak MNA, Uddin MH, Diab M, Azmi AS. Gastric Cancer Heterogeneity and Clinical Outcomes. Technol Cancer Res Treat 2020;19:1533033820935477. [PMID: 32799763 DOI: 10.1177/1533033820935477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
7 Sokolova O, Naumann M. NF-κB Signaling in Gastric Cancer.Toxins (Basel). 2017;9:119. [PMID: 28350359 DOI: 10.3390/toxins9040119] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 17.8] [Reference Citation Analysis]